This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dr. Falk Pharma GmbH
Drug Names(s): RhuDex
Description: RhuDex is a CD80 antagonist that inhibits the CD80-CD28 interaction and subsequent activation and proliferation of T cells and thus has an immunomodulating and anti-inflammatory effect. It is being developed as a DMARD for autoimmune diseases such as rheumatoid arthritis.
Avidex & Active
In April 2002, Avidex entered into an exclusive licence agreement with Active Biotech AB, covering Active Biotechs patented small molecule CD80 antagonists. The licensing agreement gives Avidex the exclusive right to evaluate further the CD80 antagonists, and to develop and market products incorporating them or their derivatives. If Avidex successfully develops the CD80 antagonists into products, Active Biotech will receive pre-agreed milestone payments and royalties on future sales.
From this work, Avidex selected RhuDex.
MediGene & Avidex
In August 2006, MediGene AG announced that it signed an agreement on the acquisition of Avidex.
MediGene & Falk
In March 2014, Medigene has signed an exclusive global licence agreement with Dr. Falk Pharma GmbH (Falk Pharma) for the development and commercialization of RhuDex for indications in hepatology and gastroenterology. Falk Pharma will assume responsibility and all costs relating to...See full deal structure in Biomedtracker
Partners: Active Biotech AB MediGene AG
Additional information available to subscribers only: